Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Cancer Sci. 2018 Dec;109(12):3993-4002. doi: 10.1111/cas.13806. Epub 2018 Nov 16.
Cancer Sci. 2018.
PMID: 30447042
Free PMC article.